Pyelonephritis in Pediatric Uropathic Patients: Differences from Community-Acquired Ones and Therapeutic Protocol Considerations. A 10-Year Single-Center Retrospective Study.
Pediatric Urology
antibiotic resistant
antibiotic therapy
pyelonephritis
uropathogens
vesicoureteral reflux
Journal
Children (Basel, Switzerland)
ISSN: 2227-9067
Titre abrégé: Children (Basel)
Pays: Switzerland
ID NLM: 101648936
Informations de publication
Date de publication:
23 May 2021
23 May 2021
Historique:
received:
05
04
2021
revised:
17
05
2021
accepted:
21
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
Pyelonephritis (PN) represents an important cause of morbidity in the pediatric population, especially in uropathic patients. The aim of the study is to demonstrate differences between PNs of uropathic patients and PNs acquired in community in terms of uropathogens involved and antibiotic sensitivity; moreover, to identify a proper empiric therapeutic strategy. A retrospective study was conducted on antibiograms on urine cultures from PNs in vesicoureteral reflux (VUR) patients admitted to pediatric surgery department and from PNs in not VUR patients admitted to Pediatric Emergency Unit between 2010 and 2020. We recorded 58 PNs in 33 patients affected by VUR and 112 PNs in the not VUR group. The mean age of not VUR patients at the PN episode was 1.3 ± 2.6 years (range: 20 days of life-3 years), and almost all the urine cultures, 111 (99.1%), isolated Gram-negative bacteria and rarely, 1 (0.9%), Gram-positive bacteria. The Gram-negative uropathogens isolated were
Identifiants
pubmed: 34071019
pii: children8060436
doi: 10.3390/children8060436
pmc: PMC8224700
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Pediatrics. 2018 Jul;142(1):
pubmed: 29954832
Pediatrics. 2008 Sep;122(3):486-90
pubmed: 18762516
JAMA. 2007 Dec 26;298(24):2895-904
pubmed: 18159059
Int J Antimicrob Agents. 2019 Nov;54(5):531-537
pubmed: 31437486
Pediatr Infect Dis J. 2017 Jan;36(1):113-115
pubmed: 27741093
JAMA Pediatr. 2018 Jun 1;172(6):550-556
pubmed: 29710324
Front Cell Infect Microbiol. 2018 May 31;8:167
pubmed: 29904624
Pediatrics. 2011 Sep;128(3):595-610
pubmed: 21873693
Pediatr Clin North Am. 2006 Jun;53(3):379-400, vi
pubmed: 16716786
J Infect. 2006 Jul;53(1):25-9
pubmed: 16269177
Proc Natl Acad Sci U S A. 1975 Jul;72(7):2621-5
pubmed: 1101260
Pediatrics. 1999 Jul;104(1 Pt 1):79-86
pubmed: 10390264
Infect Control Hosp Epidemiol. 2008 Nov;29(11):996-1011
pubmed: 18947320
J Pediatr. 2016 Apr;171:116-21
pubmed: 26794472
BMJ. 2016 Mar 15;352:i939
pubmed: 26980184
Cochrane Database Syst Rev. 2014 Jul 28;(7):CD003772
pubmed: 25066627
Intern Emerg Med. 2012 Oct;7 Suppl 3:S271-81
pubmed: 23073868
Front Cell Infect Microbiol. 2020 Dec 15;10:555508
pubmed: 33384966
BMJ Clin Evid. 2010 Feb 09;2010:
pubmed: 21733199
Am J Infect Control. 2017 Nov 1;45(11):e143-e147
pubmed: 28780198
Pediatrics. 2007 Oct;120(4):e922-8
pubmed: 17875650
Front Cell Infect Microbiol. 2017 Nov 27;7:488
pubmed: 29230385
Dan Med Bull. 2011 Apr;58(4):B4187
pubmed: 21466767
J Urol. 2005 Mar;173(3):949-54
pubmed: 15711347
J Hosp Infect. 2005 Aug;60(4):348-52
pubmed: 15923060
BMC Infect Dis. 2014 Oct 12;14:393
pubmed: 25308184
Nat Rev Urol. 2015 Feb;12(2):81-90
pubmed: 25600098
Nat Rev Urol. 2018 Dec;15(12):735-749
pubmed: 30315209
Expert Rev Anti Infect Ther. 2018 Apr;16(4):269-287
pubmed: 29617188
J Urol. 2013 Jul;190(1):222-7
pubmed: 23369720
JAMA Pediatr. 2016 Sep 1;170(9):848-54
pubmed: 27455161
Urology. 2019 Apr;126:10-15
pubmed: 30615894
Microbiol Spectr. 2016 Apr;4(2):
pubmed: 27227294
Acad Pediatr. 2019 Mar;19(2):209-215
pubmed: 30415079
J Korean Med Sci. 2019 Jun 02;34(21):e156
pubmed: 31144480
Eur Urol. 2015 Mar;67(3):546-58
pubmed: 25477258
Clin Infect Dis. 2004 Feb 1;38(3):329-34
pubmed: 14727201
J Med Microbiol. 2019 Oct;68(10):1471-1478
pubmed: 31418671